AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30322353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids (4-day course)
Number of subjects: 36
Study 30322353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4-day course)
Number of subjects: 36
Study 30322353 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy (with or without steroids)
Number of subjects: 36
Study 30296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved cookstove system using sustainably produced biomass pellets and fan micro-gasification stove
Number of subjects: 48
Study 30296300 — intervention group
Group type: COMPARATOR
Intervention: Non-adoption of improved cookstove system
Number of subjects: 48
Study 27926630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine
Number of subjects: 4
Study 25269777 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via a single, subcutaneous, 1-mL injection every 2 weeks (Q2W) as add-on therapy to atorvastatin or rosuvastatin
Number of subjects: 650
Study 25269777 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/d as add-on therapy to statin
Number of subjects: 650
Study 25269777 — intervention group
Group type: COMPARATOR
Intervention: Statin up-titration
Number of subjects: 650
Study 25269777 — intervention group
Group type: COMPARATOR
Intervention: Switch from atorvastatin to rosuvastatin
Number of subjects: 650
Study 22313193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stents
Number of subjects: 206
Study 22313193 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 206
Study 20851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein with low content of minerals
Number of subjects: 57
Study 20851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein with high content of minerals
Number of subjects: 57
Study 20851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein with low content of minerals
Number of subjects: 57
Study 20851310 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein with high content of minerals
Number of subjects: 57
Study 17174082 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency neuromuscular electrical stimulation (hf-NMES) at 50Hz for 6 weeks
Number of subjects: 17
Study 17174082 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 17
Study 17174082 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency neuromuscular electrical stimulation (hf-NMES)
Number of subjects: 17
Study 15515655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemid administration
Number of subjects: 20
Study 15515655 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 20
Study 11172139 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral-blood cells mobilized with filgrastim
Number of subjects: 172
Study 11172139 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 172
Study 11172139 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral-blood cells
Number of subjects: 172
Study 9753069 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 831
Study 9753069 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 831
Study 7921322 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in invitation letters
Number of subjects: 3874
Study 7921322 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a brochure with the recruitment mailing
Number of subjects: 3874
Study 7921322 — intervention group
Group type: EXPERIMENTAL
Intervention: Options for interview location
Number of subjects: 3874
Study 7921322 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (60 to 74 years)
Number of subjects: 3874
Study 7921322 — intervention group
Group type: EXPERIMENTAL
Intervention: Home location (rural vs. Rochester city)
Number of subjects: 3874
Study 3281058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (8 mg/kg/d)
Number of subjects: 22
Study 3281058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31728632 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg aerosol furosemide
Number of subjects: 15
Study 31728632 — intervention group
Group type: COMPARATOR
Intervention: aerosol saline
Number of subjects: 15
Study 30773358 — intervention group
Group type: EXPERIMENTAL
Intervention: First constrained liner
Number of subjects: 554
Study 30773358 — intervention group
Group type: EXPERIMENTAL
Intervention: Second constrained liner
Number of subjects: 554
Study 30773358 — intervention group
Group type: EXPERIMENTAL
Intervention: Third constrained liner
Number of subjects: 554
Study 28051969 — intervention group
Group type: EXPERIMENTAL
Intervention: TMARP plus NMES (n = 23)
Number of subjects: 44
Study 28051969 — intervention group
Group type: COMPARATOR
Intervention: TMARP alone (n = 21)
Number of subjects: 44
Study 25027030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0
Study 25027030 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study 24011687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 108
Study 24011687 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 108
Study 20729007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) within 77 days after BCS
Number of subjects: 964
Study 20729007 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) after 77 days
Number of subjects: 964
Study 20729007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) within 48 days
Number of subjects: 964
Study 20729007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) between 49-77 days
Number of subjects: 964
Study 20729007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) between 78-112 days
Number of subjects: 964
Study 19450288 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game upgrade package
Number of subjects: 330
Study 19450288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 330
Study 16306801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 4 weeks
Number of subjects: 20
Study 11943969 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 92
Study 11943969 — intervention group
Group type: COMPARATOR
Intervention: Standard psychosocial care (Control Group)
Number of subjects: 92
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: EIB test (submaximal treadmill run)
Number of subjects: 58
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-EIB test (submaximal treadmill run while inhaling cold air -20 degrees C)
Number of subjects: 58
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacholine inhalation test
Number of subjects: 58
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: EIB test
Number of subjects: 58
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-EIB test
Number of subjects: 58
Study 9616531 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacholine provocation test
Number of subjects: 58
Study 7630692 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of MPH
Number of subjects: 12
Study 7630692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of MPH
Number of subjects: 12
Study 7630692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7630692 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH (both doses)
Number of subjects: 12
Study 320809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 26
Study 320809 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 26
Study 31374471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n = 20)
Number of subjects: 55
Study 31374471 — intervention group
Group type: COMPARATOR
Intervention: Epilepsy information and self-management program (EpINFO, n = 24)
Number of subjects: 55
Study 31374471 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC, n = 11)
Number of subjects: 55
Study 28002229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 70
Study 28002229 — intervention group
Group type: COMPARATOR
Intervention: Palpation (group Palp)
Number of subjects: 70
Study 25823738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (< 20 ng/mL) in SWOG cohort
Number of subjects: 100
Study 25823738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (< 10 ng/mL) in LYSA cohort
Number of subjects: 100
Study 23555035 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for mothers and infants, initiated at 14 weeks of pregnancy
Number of subjects: 217
Study 23555035 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) for mothers and infants, initiated at 28 weeks of pregnancy (prior PMTCT recommendations)
Number of subjects: 217
Study 21546222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 72
Study 21546222 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 72
Study 21546222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19275278 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 1095
Study 19275278 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 1095
Study 19275278 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 1095
Study 19275278 — intervention group
Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 1095
Study 19275278 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (10 mg/kg/day)
Number of subjects: 1095
Study 17067452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) transplantation
Number of subjects: 50
Study 17067452 — intervention group
Group type: COMPARATOR
Intervention: Dental implant therapy alone (Control)
Number of subjects: 50
Study 15037413 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP: 30% protein, 40% carbohydrate, 30% fat)
Number of subjects: 35
Study 15037413 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet (HC: 15% protein, 55% carbohydrate, 30% fat)
Number of subjects: 35
Study 15037413 — intervention group
Group type: COMPARATOR
Intervention: Both diets (HP and HC)
Number of subjects: 35
Study 11323580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ligation-sclerotherapy (SLS)
Number of subjects: 86
Study 11323580 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 86
Study 9135361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1
Number of subjects: 30
Study 9135361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.5 micrograms kg‐1
Number of subjects: 30
Study 9135361 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 7965279 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once a day
Number of subjects: 146
Study 7965279 — intervention group
Group type: COMPARATOR
Intervention: Captopril 100 mg twice a day
Number of subjects: 146
Study 3604959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 3% NaBr solution (1 cc per kg body weight)
Number of subjects: 7
Study 3604959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 3% NaBr solution (3 times over 6 weeks)
Number of subjects: 7
Study 29844496 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 39
Study 29844496 — intervention group
Group type: COMPARATOR
Intervention: MDMA
Number of subjects: 39
Study 26071431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study with large numbers of clusters and individual participants
Number of subjects: 0
Study 26071431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot studies
Number of subjects: 0
Study 24599111 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381
Study 24599111 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381
Study 23782932 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace (integrated elderly care model)
Number of subjects: 0
Study 23782932 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 20724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (endovascular cooling to 33°C for 24 hours followed by 12 hours of controlled rewarming)
Number of subjects: 59
Study 20724711 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (standard treatment)
Number of subjects: 59
Study 20724711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 59
Study 20724711 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 59
Study 19008675 — intervention group
Group type: EXPERIMENTAL
Intervention: AERO+ST (Aerobic combined with strength training)
Number of subjects: 33
Study 19008675 — intervention group
Group type: EXPERIMENTAL
Intervention: AERO+RA (Aerobic combined with recreational activities)
Number of subjects: 33
Study 15965989 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 11
Study 15965989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12376472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic/hydrophobic-DNA adducts in white blood cells (WBC)
Number of subjects: 262
Study 12376472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GSTM1 null/GSTP1 Val genotype
Number of subjects: 262
Study 12376472 — intervention group
Group type: COMPARATOR
Intervention: GSTM1 non-null/GSTP1 Ile genotype
Number of subjects: 262
Study 10369626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral agents (stavudine, lamivudine, saquinavir soft-gel capsules, nelfinavir, efavirenz)
Number of subjects: 0
Study 10369626 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, cidofovir, famciclovir, valacyclovir, itraconazole suspension
Number of subjects: 0
Study 10369626 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal-based amphotericin products
Number of subjects: 0
Study 7771038 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated thermo-infusion dispenser with trental and actovegin for 120-hour infusion therapy
Number of subjects: 21
Study 7771038 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional methods)
Number of subjects: 21
Study 7771038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (not specified intervention)
Number of subjects: 21
Study 2181951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 113
Study 2181951 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 113
Study 379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodative training
Number of subjects: 0
Study 379112 — intervention group
Group type: COMPARATOR
Intervention: Perceptual-motor training (Control)
Number of subjects: 0
Study 31971403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG, treating team received PAT summary)
Number of subjects: 122
Study 31971403 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, no summary)
Number of subjects: 122
Study 31971403 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients and siblings
Number of subjects: 122
Study 30609983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemedicine system with glucometers and advice on medication, diet, and exercise
Number of subjects: 91
Study 30609983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemedicine system
Number of subjects: 91
Study 30609983 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient care (Control)
Number of subjects: 91
Study 28071654 — intervention group
Group type: EXPERIMENTAL
Intervention: SES‐CD
Number of subjects: 112
Study 28071654 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 112
Study 25700323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone (FML) and 0.1% sodium hyaluronate (HA)
Number of subjects: 40
Study 25700323 — intervention group
Group type: COMPARATOR
Intervention: 0.5% cyclosporin A (CsA) and 0.1% HA
Number of subjects: 40
Study 23932438 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC solifenacin 6 mg plus TOCAS 0.4 mg
Number of subjects: 1334
Study 23932438 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC solifenacin 9 mg plus TOCAS 0.4 mg
Number of subjects: 1334
Study 23932438 — intervention group
Group type: COMPARATOR
Intervention: TOCAS 0.4 mg
Number of subjects: 1334
Study 23932438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study 22372283 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-day course providing training in communication, emotional and spiritual support, and personal introspection on death anxiety.
Number of subjects: 150
Study 22372283 — intervention group
Group type: COMPARATOR
Intervention: Control group of HCWs who cared for dying patients in settings other than palliative care units.
Number of subjects: 150
Study 19255379 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive stepped-care program (n = 86)
Number of subjects: 170
Study 19255379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 84)
Number of subjects: 170
Study 16703972 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine drug testing
Number of subjects: 500
Study 16703972 — intervention group
Group type: COMPARATOR
Intervention: Previous data comparison
Number of subjects: 500
Study 16703972 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 500
Study 15596188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled TUMT at approximately 55 degrees C
Number of subjects: 42
Study 15596188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled TUMT at approximately 70 degrees C
Number of subjects: 42
Study 15596188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled TUMT
Number of subjects: 42
Study 11306519 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 22
Study 11306519 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 22
Study 11306519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 22
Study 10759688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 26
Study 10759688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8829019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily (increased to 400 mg twice daily if no improvement after 72 hours)
Number of subjects: 162
Study 8829019 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 960 mg twice daily
Number of subjects: 162
Study 1601317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical enprostil
Number of subjects: 188
Study 1601317 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 188
Study 4046609 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 micrograms dihydrotestosterone (DHT) infusion
Number of subjects: 0
Study 4046609 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 micrograms estradiol (E2) infusion
Number of subjects: 0
Study 29795532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with bupivacaine injection
Number of subjects: 131
Study 29795532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with ropivacaine injection
Number of subjects: 131
Study 29795532 — intervention group
Group type: COMPARATOR
Intervention: Control group without DPNB or PRB injection
Number of subjects: 131
Study 26739146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein bypass surgery
Number of subjects: 600
Study 26739146 — intervention group
Group type: COMPARATOR
Intervention: Best endovascular treatment (angioplasty or stenting)
Number of subjects: 600
Study 24667938 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 1500
Study 24667938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 22409379 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy in older patients
Number of subjects: 100
Study 22409379 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy in younger patients
Number of subjects: 100
Study 22409379 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections during induction in older patients
Number of subjects: 100
Study 22409379 — intervention group
Group type: COMPARATOR
Intervention: Infections during induction in younger patients
Number of subjects: 100
Study 22409379 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug reductions in older patients
Number of subjects: 100
Study 22409379 — intervention group
Group type: COMPARATOR
Intervention: Drug reductions in younger patients
Number of subjects: 100
Study 19958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/day
Number of subjects: 88
Study 19958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 or 300 mg/day
Number of subjects: 88
Study 19958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 or 300 mg/day)
Number of subjects: 88
Study 17907102 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide (CC/HCTZ), 16 mg plus 12.5 mg
Number of subjects: 203
Study 17907102 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 203
Study 16076985 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment
Number of subjects: 72
Study 16076985 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 72